1/9 Something seemed familiar about the Q498R mutation. Then I remembered: @_b_meyer, examining in-vitro evolution of RBD mutations, predicted this mutation could emerge & lead to a variant with higher infectivity & immune evasion than any existing ones. nature.com/articles/s4156…
2/9 Q498R was not just one of many mutations they predicted: it was far & away their top candidate to become a major RBD mutation. It's the only novel mutation they mention in the abstract, noting that it requires the N501Y mutation to confer increased ACE2 binding affinity.
3/9 They used yeast to display human ACE2 receptors, then let various versions of SARS-CoV-2 S RBD compete against one another, with the highest binding-affinity RBDs advancing to the next round.
4/9 Random mutations were introduced in ways I'm not competent to explain, so I've included the relevant description in the screenshot below.
5/9 Mutations common in known VOCs quickly emerged, especially E484K and N501Y, which quickly became dominant. To me, this seems a good indication that their methods are valid & useful.
6/9 For library B5, they used ACE2 that required extremely high binding affinity, & this "resulted in the fixation of mutations E484K, Q498R and N501Y in all sequenced clones." Q498R was present in all the RBD variants with the highest binding affinity.
7/9 Figure 2f shows binding affinity on the x-axis and makes clear the ability of Q498R to increase ACE 2 binding affinity, hence their prediction that this mutation could emerge & spread.
8/9 Perhaps even more worrying, computer modeling by this team indicates that Q498R could confer a significant amount of immune evasion on any variant possessing it. No wonder this new SA variant is the first to worry @GuptaR_lab since the emergence of Delta.
9/9 I'm not an expert, so if I've made any errors or mischaracterized anything above, I welcome corrections from real experts. Besides @_b_meyer, the only other authors on the study on Twitter I could find were @Matthew_Gagne_ and @Nadav_Elad.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
• BA.2.87.1 - Appeared suddenly Sept 2023, spread across South Africa, & was detected in WW in Thailand. Then basically disappeared after Dec 2023 (apart from 1 seq collected in May 2024 from Eswatini). Emerged just when JN.1 was sweeping—bad timing. 2/
• BA.2.83 - One of several BA.2 saltation variants that emerged in late 2022. First appeared in India, then in Denmark, Canada, and Australia. Could not compete with BA.2.75 and BA.5 though and disappeared without making any real impact. 3/
A mysterious, unusually diverse saltation lineage descended from KP.3.1.1 (last seen early 2025) has circulated at a low level for ~8 months in Ontario (see 🧵on next post).
Seemed a local anomaly, but @solidevidence just spied a weird spike in NYC WW—& it's the same one!
1/14
Wildly diverse branch of MC.10.1.7 (KP.3.1.1 descendant, died out early 2025) in Ontario.
It's apparently been circulating at a low level for the past year. ≥6 different people are represented here.
I think this must involve one or more chronic infections + transmission. 1/7
• Busy 630 loop: ∆621-622 + NVFQ->IFPMAE at S:641-644.
• 2-nuc muts: W452K + D839K.
• Ultra-rare S2 insertion: ins791P
M:H155N, ORF1a:R3164H, & ORF3a:255-256 deletions cluster in chronics, often w/S:D936H/Y or ORF1a:L3201P. Intriguingly, D936Y was in the last seq. 2/7
More info on this unusual branch can be found on the Github page for undesignated lineages, which Fede Gueli tirelessly and selflessly keeps up to date.
Another fantastic preprint on BA.3.2's propensity for children, this time from @yunlong_cao & co.
They not only confirm the findings of David Ho's lab (that kids have ~0 antibody response to BA.3.2) but dig into the details of exactly why kids are so vulnerable to BA.3.2.
1. Kids vaccinated before being infected have robust antibodies against BA.3.2
2. Unvaxed adults much more vulnerable to BA.3.2, esp. compared to mRNA-vaxed adults.
Read @yunlong_cao's 🧵 & very readable paper for details. 2/4
There's still one major paradox here I can't wrap my head around: countries with the highest vaccination rates & the lowest proportion of children appear—very low sequencing makes hard conclusions difficult—to have the highest proportion of BA.3.2. 3/4
New data from David Ho's lab showing that while adults & kids have ~equal antibody responses to XFG & NB.1.8.1, children have essentially no neutralizing antibodies to BA.3.2.
This seems to largely solve the BA.3.2 + kids mystery. 1/14
If you've missed the story about how BA.3.2 (a novel, divergent saltation variant) is hugely overrepresented in sequences from children, this was my original (very quick) analysis, which subsequent data extended & confirmed. 2/
More details from this preprint. 50 is the limit of detection (i.e. zero). Nearly all kids under 7 had no detectable nAbs to BA.3.2, despite robust nAb titers against NB.1.8.1 & XFG.
I've tried to make sense of BA.3.2's penchant for kids by considering its unique spike: more compact, more closed, & more antibody-evasive than any other variant.
But I think another feature of BA.3.2 is responsible: its wholesale deletion of ORF7a, ORF7b, & ORF8 (∆ORF78).
2/
∆ORF78 is rare but not unheard of; it was in several late XBB variants (GW.5.1.1, FW.1.1, GE.1.2, etc) & a few branches of other variants. I've long thought these late XBB had an advantage in some population subsector, but I didn't suspect kids. 3/